Sequential Bevacizumab-based therapy in metastatic colorectal cancer (mCRC): results of a treatment sequencing cost analysis

被引：0
|
作者：
Rautenberg, T. [1 ]
Siebert, U. [2 ]
Arnold, D. [3 ]
Bennouna, J. [4 ]
Kubicka, S. [5 ]
Walzer, S. [1 ]
Ngoh, C. [6 ]
机构：
[1] AiM Assessment Med GmbH, Lorrach, Germany
[2] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth & Hlth Technol Assessment, Hall In Tirol, Austria
[3] Univ Hosp, Hubertus Wald Tumor Ctr, UCCH, Eppendorf, Germany
[4] Inst Cancerol Quest, Nantes, Saint Herblain, France
[5] Hannover Med Sch, D-30623 Hannover, Germany
[6] F Hoffmann La RocheLa Roche AG, Basel, Switzerland
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [31] CHOICE OF SEQUENTIAL BIOLOGICAL THERAPIES IN METASTATIC COLORECTAL CANCER (MCRC): A COST COMPARISON ANALYSIS FOR WILD-TYPE KRAS MCRC PATIENTS IN BRAZIL
    Tsuchiya, C. T.
    Kim, H. S.
    La Scala, C. S.
    VALUE IN HEALTH, 2015, 18 (03) : A197 - A197
  • [32] Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients
    Vincenzi, Bruno
    Zoccoli, Alice
    Schiavon, Gaia
    Iuliani, Michele
    Pantano, Francesco
    Dell'Aquila, Emanuela
    Ratta, Raffaele
    Muda, Andrea Onetti
    Perrone, Giuseppe
    Brunelli, Chiara
    Correale, Pierpaolo
    Riva, Elisabetta
    Russo, Antonio
    Loupakis, Fotios
    Falcone, Alfredo
    Santini, Daniele
    Tonini, Giuseppe
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1501 - 1508
  • [33] IMPACT OF TUMOUR SITE ON BEVACIZUMAB EFFICACY IN METASTATIC COLORECTAL CANCER (mCRC)
    Wong, H.
    Field, K.
    Lomax, A.
    Tacey, M.
    Shapiro, J.
    McKendrick, J.
    Zimet, A.
    Yip, D.
    Nott, L.
    Jennens, R.
    Richardson, G.
    Tie, J.
    Kosmider, S.
    Parente, P.
    Lim, L.
    Cooray, P.
    Tran, B.
    Desai, J.
    Wong, R.
    Gibbs, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 46 - 46
  • [34] Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
    Giantonio, Bruce J.
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S15 - S18
  • [35] Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy.
    Miyamoto, Yuji
    Loupakis, Fotios
    Zhang, Wu
    Cao, Shu
    Okazaki, Satoshi
    Berger, Martin D.
    Suenaga, Mitsukuni
    Schirripa, Marta
    Soni, Shivani
    Matsusaka, Satoshi
    Ning, Yan
    Yang, Dongyun
    Gopez, Roel
    Melendez, Elizabeth
    Hanna, Diana L.
    Barzi, Afsaneh
    Baba, Hideo
    Falcone, Alfredo
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] DICER AND DROSHA EXPRESSION AND RESPONSE TO BEVACIZUMAB-BASED THERAPY IN ADVANCED COLORECTAL CANCER PATIENTS
    Zoccoli, A.
    Iuliani, M.
    Pantano, F.
    Schiavon, G.
    Ratta, R.
    Correale, P.
    Muda, A. Onetti
    Santini, D.
    Tonini, G.
    Vincenzi, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 530 - 530
  • [37] High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis
    Zhao, Lei
    Zhang, Dejun
    Ma, Hong
    Jin, Min
    Huang, Fang
    Zhang, Tao
    PANMINERVA MEDICA, 2016, 58 (01) : 48 - 58
  • [38] Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial
    Kurreck, Annika
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kaiser, Florian
    Uhlig, Jens
    Schenk, Michael
    Freiberg-Richter, Jens
    Peuser, Bettina
    Denzlinger, Claudio
    Graeven, Ullrich
    Heinrich, Kathrin
    Held, Swantje
    Stahler, Arndt
    Alig, Annabel Helga Sophie
    Jelas, Ivan
    von Einem, Jobst C.
    Stintzing, Sebastian
    Giessen-Jung, Clemens
    Modest, Dominik P.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer
    Shingo Tamura
    Hitoshi Kusaba
    Naoki Kubo
    Kayo Ijichi
    Kenji Tsuchihashi
    Masato Komoda
    Keita Uchino
    Hiroshi Ariyama
    Koichi Akashi
    Eishi Baba
    Medical Oncology, 2014, 31
  • [40] BEVACIZUMAB plus CHEMOTHERAPY BEYOND FIRST PROGRESSION IN METASTATIC COLORECTAL CANCER PATIENTS PREVIOUSLY TREATED WITH BEVACIZUMAB-BASED THERAPY: TML STUDY SUBGROUP FINDINGS
    Andre, Thierry
    Jose Maria, Vieitez
    Bouche, Olivier
    Bennouna, Jaafar
    Sastre, Javier
    Alonso-Orduna, Vicente
    Arnold, Dirk
    Osterlund, Pia
    Greil, Richard
    Van Cutsem, Eric
    von Moos, Roger
    Reyes-Rivera, Irmarie
    Makrutzki, Martina
    Kubicka, Stefan
    ANNALS OF ONCOLOGY, 2012, 23 : 14 - 14
12345